5 Jun 2020 09:02
Oncimmune Holdings plc
Β
("Oncimmune" or the "Company")
Β
CORRECTION: Director/PDMR's Dealing
Β
The Director/PDMR Dealing announcement released this morning has been amended as follows: the weighted average price paid by Meinhard and Tatiana Schmidt has been corrected to Β£1.185 and the date that the Company was notified of dealings by the Director/PDMRs was 4 June 2020. All other details remain the same. The full amended text is shown below.
Β
Director/PDMR's Dealing
Β
Oncimmune Holdings plc (AIM: ONC.L),Β the leading global immunodiagnostics group, was informed that, on 4 June 2020, dealings in the Company's ordinary shares of Β£0.01 each in the Company ("Ordinary Shares") by the following Director / PDMRs had occurred:
Β
- Meinhard Schmidt, Non-Executive Chairman, together with his wife and PCA, Tatiana Schmidt, acquired in aggregate 13,000 Ordinary Shares at a weighted average price of Β£1.185 per share
Β
- Tim Bunting, Non-Executive Director, acquired 150,000 Ordinary Shares at a weighted average price of Β£1.192 per share
Β
- Adam Hill, Chief Executive Officer, acquired 8,481 Ordinary Shares at a price of Β£1.179 per share
Β
- Matthew Hall, Chief Financial Officer, acquired 1,272 Ordinary Shares at a price of Β£1.179 per share
Β
- Ron Kirschner, General Counsel and Company Secretary, acquired 1,652 Ordinary Shares at a price of Β£1.204 per share
Β
Β
Director/PDMR/ PCA | No. of Ordinary Shares acquired | Resulting interest | Resulting % holding |
Meinhard Schmidt / Tatiana Schmidt | 13,000 | 31,000 | 0.05% |
Tim Bunting | 150,000 | 2,956,717 | 4.7% |
Adam Hill | 8,481 | 40,913 | 0.06% |
Matthew Hall | 1,272 | 11,935 | 0.02% |
Ron Kirschner | 1,652 | 1,652 | 0.003% |
Β
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
Β
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name | Meinhard Schmidt / Tatiana Schmidt | |||
2 Β | Reason for the notification | ||||
a) Β | Position/status Β | Non-executive Chairman / PCA | |||
b) Β | Initial notification /Amendment | Initial notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Β | ||||
a) Β | Name Β | Oncimmune Holdings plc | |||
b) Β | LEI | 213800HCYIWT6YPI1I02Β | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary Shares of Β£0.01 each Β | |||
Β | Β | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
Β | Β | ||||
b) Β | Nature of the transaction | Purchase of shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price | Volume | Β | |
Β | Β | Β£1.17 | 8,000 | Β | |
Β | Β | Β£1.21 | 5,000 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | Β | |||
Β | Β | ||||
- Aggregated volume | 13,000 shares Weighted average price of Β£1.185 | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transactionΒ | 4 June 2020 | |||
f) Β | Place of the transaction | London stock exchange, AIM | |||
Β
Β
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name | Timothy Bunting | |||
2 Β | Reason for the notification Β | ||||
a) Β | Position/status Β | Non-executive Director | |||
b) Β | Initial notification /Amendment | Initial notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) Β | Name Β | Oncimmune Holdings plc | |||
b) Β | LEI | 213800HCYIWT6YPI1I02Β | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary Shares of Β£0.01 each Β | |||
Β | Β | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
Β | Β | ||||
b) Β | Nature of the transaction Β | Purchase of shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price | Volume | Β | |
Β | Β | Β£1.195 | 60,000 | Β | |
Β | Β | Β£1.19 | 90,000 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | Β | |||
Β | Β | ||||
- Aggregated volume | 150,000 shares Weighted average price of Β£1.192 | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transactionΒ | 4 June 2020 | |||
f) Β | Place of the transaction | London stock exchange, AIM | |||
Β
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name | Dr Adam Mark Hill | |||
2 Β | Reason for the notification Β | ||||
a) Β | Position/status Β | Chief Executive Officer | |||
b) Β | Initial notification /Amendment | Initial notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Β | ||||
a) Β | Name Β | Oncimmune Holdings plc | |||
b) Β | LEI | 213800HCYIWT6YPI1I02Β | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Β Β | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary Shares of Β£0.01 each Β | |||
Β | Β | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
Β | Β | ||||
b) Β | Nature of the transaction Β | Purchase of shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price | Volume | Β | |
Β | Β | Β£1.179 | 8,481 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | Β | |||
Β | Β | ||||
- Aggregated volume | Same as above | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transactionΒ | 4 June 2020 | |||
f) Β | Place of the transaction Β | London stock exchange, AIM | |||
Β
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name | Matthew Hall | |||
2 Β | Reason for the notification Β | ||||
a) Β | Position/status Β | Chief Financial Officer | |||
b) Β | Initial notification /Amendment | Initial notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Β | ||||
a) Β | Name Β | Oncimmune Holdings plc | |||
b) Β | LEI | 213800HCYIWT6YPI1I02Β | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary Shares of Β£0.01 each Β | |||
Β | Β | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
Β | Β | ||||
b) Β | Nature of the transaction | Purchase of shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price | Volume | Β | |
Β | Β | Β£117.9 | 1,272 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | Β | |||
Β | Β | ||||
- Aggregated volume | Same as above | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transactionΒ | 4 June 2020 | |||
f) Β | Place of the transaction | London stock exchange, AIM | |||
Β
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name | Ron Kirschner | |||
2 Β | Reason for the notification Β | ||||
a) Β | Position/status | General Counsel and Company Secretary | |||
b) Β | Initial notification /Amendment | Initial notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) Β | Name | Oncimmune Holdings plc | |||
b) Β | LEI | 213800HCYIWT6YPI1I02Β | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary Shares of Β£0.01 each Β | |||
Β | Β | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
Β | Β | ||||
b) Β | Nature of the transaction | Purchase of shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price | Volume | Β | |
Β | Β | Β£1.204 | 1,652 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | Β | |||
Β | Β | ||||
- Aggregated volume | Same as above | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transactionΒ | 4 June 2020 | |||
f) Β | Place of the transaction | London stock exchange, AIM | |||
Β
Β
For further information:
Β
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com Β
Β
Follow the stocks